# US 2026/0083857 A1 · Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083857 A1
- Document ID: US20260083857A1
- Status: Published application
- Kind: A1
- Application number: 19/335,771
- Filed: 2025-09-22
- Published: 2026-03-26
- Earliest claimed: 2024-09-23
- Applicants: Cephalon LLC
- Inventors: Haichen Nie; Pragya Manandhar; Zaneta Maijorovaite; Wei Liu
- Web page: https://patentgrep.com/patent/US20260083857A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- C07K 14/55: IL-2
- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C07K 2317/524: CH2 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are stable pharmaceutical formulations comprising anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugates and uses thereof.

## Claims

### Claim 1

A stable pharmaceutical formulation comprising:
18 mM to 22 mM of acetate;
50 mM to 250 mM of sucrose;
100 mM to 500 mM of glycine;
0.05% to 0.1% of PS80; and
5 mg/mL to 10 mg/mL of an anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugate comprising:
a modified hIL-2 protein comprising the amino acid sequence of SEQ ID NO: 25; and
an anti-hPD-1 antibody, or antigen-binding fragment thereof, that immunospecifically binds to hPD-1, wherein the antibody or antigen-binding fragment thereof, comprises a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 71, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 72, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 73, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 74, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 76.

### Claim 2 (depends on 1)

The stable pharmaceutical formulation of claim 1, comprising:
20 mM of acetate;
200 mM of sucrose;
400 mM of glycine; and
0.05% of PS80.

### Claim 3 (depends on 1)

The stable pharmaceutical formulation of claim 1, comprising 10 mg/mL of the anti-hPD-1 antibody-modified hIL-2 immunoconjugate.

### Claim 4 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the pH is 4.5 to 5.5.

### Claim 5 (depends on 4)

The stable pharmaceutical formulation of claim 4, wherein the pH is 5.0.

### Claim 6 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the modified hIL-2 protein further comprises a deletion or substitution at amino acid position 3.

### Claim 7 (depends on 6)

The stable pharmaceutical formulation of claim 6, wherein the substitution at amino acid position 3 of the modified hIL-2 protein is T3A.

### Claim 8 (depends on 7)

The stable pharmaceutical formulation of claim 7, wherein the modified hIL-2 protein comprises the amino acid sequence of SEQ ID NO: 36.

### Claim 9 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the modified hIL-2 protein further comprises a deletion or substitution at amino acid position 125.

### Claim 10 (depends on 9)

The stable pharmaceutical formulation of claim 9, wherein the substitution at amino acid position 125 is C125A.

### Claim 11 (depends on 10)

The stable pharmaceutical formulation of claim 10, wherein the modified hIL-2 protein comprises the amino acid sequence of SEQ ID NO: 37.

### Claim 12 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 70.

### Claim 13 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises an IgG1 heavy chain constant region.

### Claim 14 (depends on 13)

The stable pharmaceutical formulation of claim 13, wherein the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises an L235A substitution and a G237A substitution, according to EU numbering.

### Claim 15 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 67 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 68.

### Claim 16 (depends on 1)

The stable pharmaceutical formulation of claim 1, comprising:
18 mM to 22 mM of acetate;
50 mM to 250 mM of sucrose;
100 mM to 500 mM of glycine;
0.05% to 0.1% of PS80; and
5 mg/mL to 10 mg/mL of the anti-hPD-1 antibody-modified hIL-2 immunoconjugate, wherein the modified hIL-2 protein comprises the amino acid sequence of SEQ ID NO: 37 and the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises a HC comprising the amino acid sequence of SEQ ID NO: 67 and a LC comprising the amino acid sequence of SEQ ID NO: 68.

### Claim 17 (depends on 1)

The stable pharmaceutical formulation of claim 1, wherein the anti-hPD-1 antibody-modified hIL-2 immunoconjugate comprises:
a light chain comprising the amino acid sequence of SEQ ID NO: 68; and
a heavy chain-modified hIL-2 protein fusion comprising the amino acid sequence of SEQ ID NO: 83.

### Claim 18 (depends on 1)

The stable pharmaceutical formulation of claim 1, comprising 10 mg/mL of the hPD-1 antibody-modified hIL-2 immunoconjugate, 20 mM of acetate, 200 mM of sucrose, 400 mM of glycine, and 0.05% of PS80, and a pH of 5.0.

### Claim 19 (depends on 1)

The stable pharmaceutical formulation of claim 1, comprising:
20 mM of acetate;
200 mM of sucrose;
400 mM of glycine;
0.05% of PS80; and
10 mg/mL of the anti-hPD-1 antibody-modified hIL-2 immunoconjugate, wherein the modified hIL-2 protein comprises the amino acid sequence of SEQ ID NO: 37 and the anti-hPD-1 antibody, or antigen-binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 67 and a light chain comprising the amino acid sequence of SEQ ID NO: 68,
wherein the liquid pharmaceutical formulation has a pH of 5.0.

### Claim 20 (depends on 1)

A stable lyophilized pharmaceutical formulation prepared by lyophilizing the stable pharmaceutical formulation of claim 1.

### Claim 21 (depends on 20)

The stable lyophilized pharmaceutical formulation of claim 20, comprising:
acetate;
sucrose;
glycine;
PS80; and
an anti-hPD-1 antibody-modified hIL-2 immunoconjugate comprising:
a modified hIL-2 protein comprising the amino acid sequence of SEQ ID NO: 25; and
an anti-hPD-1 antibody, or antigen-binding fragment thereof, that immunospecifically binds to hPD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 71, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 72, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 73, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 74, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 76.

### Claim 22 (depends on 21)

The stable lyophilized pharmaceutical formulation of claim 21, wherein, once reconstituted, comprises 10 mg/mL of the hPD-1 antibody-modified hIL-2 immunoconjugate, 20 mM of acetate, 200 mM of sucrose, 400 mM of glycine, and 0.05% of PS80, and has a pH of 5.0.

### Claim 23 (depends on 1)

A method of treating a cancer in a subject, the method comprising:
administering a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 to the subject to thereby treat the cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the stable pharmaceutical formulation comprises 10 mg/mL of the hPD-1 antibody-modified hIL-2 immunoconjugate, 20 mM of acetate, 200 mM of sucrose, 400 mM of glycine, and 0.05% of PS80, and has a pH of 5.0.

### Claim 25 (depends on 23)

The method of claim 23, wherein the cancer is a melanoma, a Merkel cell carcinoma, a non-small cell lung carcinoma, a renal cell carcinoma, a triple negative breast cancer, a squamous cell carcinoma of the head/neck, a hepatocellular carcinoma, or microsatellite instability-high tumors or tumors with deficient DNA mismatch repair.
